Dr. Spira on the Updated Results of the CHRYSALIS Trial in EGFR-Mutant NSCLC
Note: The CHRYSALIS Trial, involves a combination of amivantamab and lazertinib in patients with Tagrisso-relapsed and chemo naïve cancer.
Alexander Spira, MD, PhD, FACP, a medical oncologist and director of the Virginia Cancer Specialists Research Institute and the Phase 1 Trial Program, discusses the updated results of the phase 1 CHRYSALIS trial (NCT02609776) in EGFR-mutant non–small cell lung cancer (NSCLC).
During the 2021 ASCO Annual Meeting, updated findings from the CHRYSALIS trial were presented, demonstrating a 36% overall response rate with amivantamab-vmjw (Rybrevant) in combination with lazertinib (YH25448) in patients with osimertinib (Tagrisso)–relapsed, chemotherapy-naïve, EGFR-mutant NSCLC. The median duration of response with the combination was 9.6 months and the regimen was well tolerated.
Notably, the combination could offer patients who have progressed on a TKI an effective, chemotherapy-free, targeted option, concludes Spira. Listen here.